These studies validate the potential of IRE1α inhibitors for the prevention and treatment of obesity, insulin resistance and comorbidities, which sets the foundation for further clinical development of IRE1α inhibitors as a therapeutical direction for diabetes and obesity. The gene discussed is ERN1; the disease is obesity due to melanocortin 4 receptor deficiency.